A Curated Platform of Equity & Options Market Intelligence
Select Page

NTLA

Search by
TICKER SYMBOL

Intellia Therapeutics Inc

Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology (except Nanobiotechnology)

24.27

-0.74

(-2.959%)

Volume:

1,295,745

52 week range:

22.67 - 47.48

Market Cap:

2.333B

Company Description:

intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the